· Researchers state that post-vaccine syndrome is characterized by persistent immune dysregulation & issues with blood coagulation.
-
· Scientists found a new antiviral drug prototype that prevented Long COVID in mice and could also help treat the disease
· A recent preprint shared in medRxiv found further evidence of brain damage after COVID-19
· A new clinical trial for myalgic encephalomyelitis (ME) is recruiting in Tokyo, Japan, to test the monoclonal antibody Rituximab
Research updates, July 1 - The Sick Times
Scientists found a new antiviral drug prototype that prevented Long COVID in mice and could also help treat the disease. In a study describing this milestone, published in Nature Communications, researchers stated the antiviral targets the coronavirus’ PLpro protein, as opposed to the Mpro protein, which Paxlovid targets.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· The biotech company Invivyd, which makes the #COVID19 monoclonal antibody Pemgarda, announced that it has launched the SPEAR Study Group to explore the drug for #LongCOVID and post-vaccine syndrome (PVS)
· A new study from Taiwan published in Pediatrics and Neonatology found about 14% of children developed Long COVID after being infected with #SarsCoV2
· A new observational study is investigating the relationship between COVID-19 and #Diabetes
Research updates, July 8 - The Sick Times
The biotech company Invivyd, which makes the COVID-19 monoclonal antibody Pemgarda, announced this week that it has launched the SPEAR Study Group to explore the drug for Long COVID and post-vaccine syndrome (PVS).
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· The biotech company Invivyd, which makes the #COVID19 monoclonal antibody Pemgarda, announced that it has launched the SPEAR Study Group to explore the drug for #LongCOVID and post-vaccine syndrome (PVS)
· A new study from Taiwan published in Pediatrics and Neonatology found about 14% of children developed Long COVID after being infected with #SarsCoV2
· A new observational study is investigating the relationship between COVID-19 and #Diabetes
Research updates, July 8 - The Sick Times
The biotech company Invivyd, which makes the COVID-19 monoclonal antibody Pemgarda, announced this week that it has launched the SPEAR Study Group to explore the drug for Long COVID and post-vaccine syndrome (PVS).
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A new study in PNAS found elevated oxidative stress was a shared characteristic in both #MECFS and #LongCOVID
· RECOVER-Treating Long COVID, the clinical trials initiative run by the Foundation for the NIAID, has announced that it will hold a second annual hybrid workshop discussing the initiative’s research
· A clinical trial in the U.K. called PHOSP-I is recruiting to test the monoclonal antibody Tocilizumab
Research updates, July 15 - The Sick Times
A new study in PNAS found elevated oxidative stress was a shared characteristic in both myalgic encephalomyelitis (ME) and Long COVID.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A new study in PNAS found elevated oxidative stress was a shared characteristic in both #MECFS and #LongCOVID
· RECOVER-Treating Long COVID, the clinical trials initiative run by the Foundation for the NIAID, has announced that it will hold a second annual hybrid workshop discussing the initiative’s research
· A clinical trial in the U.K. called PHOSP-I is recruiting to test the monoclonal antibody Tocilizumab
Research updates, July 15 - The Sick Times
A new study in PNAS found elevated oxidative stress was a shared characteristic in both myalgic encephalomyelitis (ME) and Long COVID.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A treatment for cats with a #COVID19-related infection may help advance #LongCOVID research
· The supplement Oxaloacetate may help reduce fatigue for LC, but it “did not reach statistical significance,” according to a new study at Bateman Horne Center
· A new prospective cohort study in JAMA Oncology of 1,572 participants with cancer found that COVID-19 had a “significant impact” on these patients, incl. hospitalization, treatment disruptions, death
Research updates, July 22 - The Sick Times
A treatment for cats with a COVID-related infection may help advance Long COVID research. In a small study in Stem Cells Translation Medicine, researchers treated 10 cats who got feline infectious peritonitis (FIP), a feline coronavirus infection that triggers immune dysfunction, and found that those who received a combination of the antiviral drug GS-441524 and mesenchymal stem/stromal cell (MSC) therapy had “enhanced immune recovery.”
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A treatment for cats with a #COVID19-related infection may help advance #LongCOVID research
· The supplement Oxaloacetate may help reduce fatigue for LC, but it “did not reach statistical significance,” according to a new study at Bateman Horne Center
· A new prospective cohort study in JAMA Oncology of 1,572 participants with cancer found that COVID-19 had a “significant impact” on these patients, incl. hospitalization, treatment disruptions, death
Research updates, July 22 - The Sick Times
A treatment for cats with a COVID-related infection may help advance Long COVID research. In a small study in Stem Cells Translation Medicine, researchers treated 10 cats who got feline infectious peritonitis (FIP), a feline coronavirus infection that triggers immune dysfunction, and found that those who received a combination of the antiviral drug GS-441524 and mesenchymal stem/stromal cell (MSC) therapy had “enhanced immune recovery.”
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· Two studies on potential biomarkers for #MECFS were published this month
· Stellate ganglion blocks, a procedure where an anesthetic is injected into nerves in the neck, may help reduce the severity of some symptoms of #LongCOVID and ME
· An observational study is recruiting 40 people in Boston, Massachusetts to test for defects of air and blood flow in the lungs in people with Long COVID
Research updates, July 29 - The Sick Times
Two studies on potential biomarkers for myalgic encephalomyelitis (ME) were published this month. Plus, new studies about stellate ganglion blocks.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· Two studies on potential biomarkers for #MECFS were published this month
· Stellate ganglion blocks, a procedure where an anesthetic is injected into nerves in the neck, may help reduce the severity of some symptoms of #LongCOVID and ME
· An observational study is recruiting 40 people in Boston, Massachusetts to test for defects of air and blood flow in the lungs in people with Long COVID
Research updates, July 29 - The Sick Times
Two studies on potential biomarkers for myalgic encephalomyelitis (ME) were published this month. Plus, new studies about stellate ganglion blocks.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A drug originally developed for celiac disease was found to be safe and effective in treating a post-COVID syndrome in children
· “Dormant cancer cells are like the embers left in an abandoned campfire, and respiratory viruses are like a strong wind that reignites the flames,” said one of the authors of a new study in Nature
· An upcoming at-home clinical trial program for #LongCOVID, run by Scripps Research, is seeking participants
Research updates, August 5 - The Sick Times
A drug originally developed for celiac disease was found to be safe and effective in treating a post-COVID syndrome in children, according to a new paper published in Science Translational Medicine.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A drug originally developed for celiac disease was found to be safe and effective in treating a post-COVID syndrome in children
· “Dormant cancer cells are like the embers left in an abandoned campfire, and respiratory viruses are like a strong wind that reignites the flames,” said one of the authors of a new study in Nature
· An upcoming at-home clinical trial program for #LongCOVID, run by Scripps Research, is seeking participants
Research updates, August 5 - The Sick Times
A drug originally developed for celiac disease was found to be safe and effective in treating a post-COVID syndrome in children, according to a new paper published in Science Translational Medicine.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· People with myalgic encephalomyelitis (#MECFS) have significant genetic differences in their DNA
· A very small clinical trial of the infusion drug BC 007 published in eClinicalMedicine found “significant improvement” in fatigue in people with #LongCOVID
· A phase 2 clinical trial testing the monoclonal antibody sipavibart is recruiting in Fort Lauderdale, Florida
Research updates, August 12 - The Sick Times
People with myalgic encephalomyelitis (ME) have significant genetic differences in their DNA, according to a preprint shared this week from the DecodeME study.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· People with myalgic encephalomyelitis (#MECFS) have significant genetic differences in their DNA
· A very small clinical trial of the infusion drug BC 007 published in eClinicalMedicine found “significant improvement” in fatigue in people with #LongCOVID
· A phase 2 clinical trial testing the monoclonal antibody sipavibart is recruiting in Fort Lauderdale, Florida
Research updates, August 12 - The Sick Times
People with myalgic encephalomyelitis (ME) have significant genetic differences in their DNA, according to a preprint shared this week from the DecodeME study.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A new preprint from the National Institutes of Health (NIH) RECOVER study found that #COVID19 reinfections may increase risk of #LongCOVID by about 35%
· A new review article in Ageing Research Reviews found that persistent infections from viruses, bacteria, fungus, and parasites can accelerate human aging
· A new Long COVID clinical trial to test the immunotherapy drug Anktiva was announced this week by the Chan Soon-Shiong Institute for Medicine
Research updates, August 19 - The Sick Times
A new preprint from the National Institutes of Health (NIH) RECOVER study found that COVID reinfections may increase the risk of Long COVID by about 35%.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A new preprint from the National Institutes of Health (NIH) RECOVER study found that #COVID19 reinfections may increase risk of #LongCOVID by about 35%
· A new review article in Ageing Research Reviews found that persistent infections from viruses, bacteria, fungus, and parasites can accelerate human aging
· A new Long COVID clinical trial to test the immunotherapy drug Anktiva was announced this week by the Chan Soon-Shiong Institute for Medicine
Research updates, August 19 - The Sick Times
A new preprint from the National Institutes of Health (NIH) RECOVER study found that COVID reinfections may increase the risk of Long COVID by about 35%.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· Metformin may help reduce the risk of #LongCOVID, according to two new studies
· A Phase 2 clinical trial is studying the drug vidofludimus calcium (IMU-838) for Long COVID
· The National Institutes of Health’s second RECOVER-Treating Long COVID workshop is happening next week, September 9–10
Research updates, September 2 - The Sick Times
Metformin may help reduce the risk of Long COVID, according to two new studies. One large study from the United Kingdom found that it reduced the rate of Long COVID in “obese and overweight” people by 63% percent.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· Metformin may help reduce the risk of #LongCOVID, according to two new studies
· A Phase 2 clinical trial is studying the drug vidofludimus calcium (IMU-838) for Long COVID
· The National Institutes of Health’s second RECOVER-Treating Long COVID workshop is happening next week, September 9–10
Research updates, September 2 - The Sick Times
Metformin may help reduce the risk of Long COVID, according to two new studies. One large study from the United Kingdom found that it reduced the rate of Long COVID in “obese and overweight” people by 63% percent.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A medium sized study in Saudi Arabia found that 29% of participants who were infected with SARS-CoV-2 developed #LongCOVID
· In a small case series, a combination of three antivirals was effective in improving symptoms in participants with Long COVID, according to a new preprint
· The Food and Drug Administration (FDA) accepted the drug application of a potential oral therapy for the prevention of #COVID19 following exposure
Research updates, September 9 - The Sick Times
A large study in Saudi Arabia found that 29% of participants who were infected with SARS-CoV-2 developed Long COVID. “This finding is consistent with the higher prevalence estimates reported globally and highlights the long-term burden of post-acute COVID-19 symptoms,” the authors of the study, published in BMC Infectious Diseases, wrote.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A medium sized study in Saudi Arabia found that 29% of participants who were infected with SARS-CoV-2 developed #LongCOVID
· In a small case series, a combination of three antivirals was effective in improving symptoms in participants with Long COVID, according to a new preprint
· The Food and Drug Administration (FDA) accepted the drug application of a potential oral therapy for the prevention of #COVID19 following exposure
Research updates, September 9 - The Sick Times
A large study in Saudi Arabia found that 29% of participants who were infected with SARS-CoV-2 developed Long COVID. “This finding is consistent with the higher prevalence estimates reported globally and highlights the long-term burden of post-acute COVID-19 symptoms,” the authors of the study, published in BMC Infectious Diseases, wrote.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· An estimated 36% of people with a documented SARS-CoV-2 infection worldwide have experienced #LongCOVID, according to a new systematic review
· New funding will help advance a potential low-cost diagnostic test for myalgic encephalomyelitis (#ME)
· The SPEAR study group has proposed a potential Long COVID clinical trial with the company’s next-generation monoclonal antibody, VYD2311
Research updates, September 16 - The Sick Times
An estimated 36% of people with a documented SARS-CoV-2 infection worldwide have experienced Long COVID, according to a new systematic review that synthesized over 400 studies.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· An estimated 36% of people with a documented SARS-CoV-2 infection worldwide have experienced #LongCOVID, according to a new systematic review
· New funding will help advance a potential low-cost diagnostic test for myalgic encephalomyelitis (#ME)
· The SPEAR study group has proposed a potential Long COVID clinical trial with the company’s next-generation monoclonal antibody, VYD2311
Research updates, September 16 - The Sick Times
An estimated 36% of people with a documented SARS-CoV-2 infection worldwide have experienced Long COVID, according to a new systematic review that synthesized over 400 studies.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· Two recent studies found limitations of the drug Paxlovid for protection from #LongCOVID, contrasting prior studies that suggested the antiviral drug might help prevent the disease
· Long COVID may increase menstrual bleeding, according to a new survey study published in Nature Communications
· A new clinical trial is testing the supplement Mitoquinone in combination with “exercise rehabilitation” (which may be detrimental) for Long COVID
Research updates, September 23 - The Sick Times
Two recent studies found limitations of the drug Paxlovid for protection from Long COVID, contrasting prior studies that suggested the antiviral drug might help prevent this disease.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· Two recent studies found limitations of the drug Paxlovid for protection from #LongCOVID, contrasting prior studies that suggested the antiviral drug might help prevent the disease
· Long COVID may increase menstrual bleeding, according to a new survey study published in Nature Communications
· A new clinical trial is testing the supplement Mitoquinone in combination with “exercise rehabilitation” (which may be detrimental) for Long COVID
Research updates, September 23 - The Sick Times
Two recent studies found limitations of the drug Paxlovid for protection from Long COVID, contrasting prior studies that suggested the antiviral drug might help prevent this disease.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· Researchers in Spain assessed over 190,000 participants, found that #LongCOVID prevalence was three to 10 times higher in individuals with three or more reported infections
· A new RECOVER study published in JAMA found that olfactory dysfunction, or changes to sense of smell, occurred in people after SARS-CoV-2 infection
· A behavioral trial at Columbia University (LONG-CALM) is assessing a vague “mindfulness intervention” for Long COVID
Research updates, September 30 - The Sick Times
Researchers in Spain assessed over 190,000 participants, using data from a public health research network, in a study published in the journal Vaccines. They found that Long COVID prevalence was three to 10 times higher in individuals with three or more reported infections than in those with only one infection.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· Researchers in Spain assessed over 190,000 participants, found that #LongCOVID prevalence was three to 10 times higher in individuals with three or more reported infections
· A new RECOVER study published in JAMA found that olfactory dysfunction, or changes to sense of smell, occurred in people after SARS-CoV-2 infection
· A behavioral trial at Columbia University (LONG-CALM) is assessing a vague “mindfulness intervention” for Long COVID
Research updates, September 30 - The Sick Times
Researchers in Spain assessed over 190,000 participants, using data from a public health research network, in a study published in the journal Vaccines. They found that Long COVID prevalence was three to 10 times higher in individuals with three or more reported infections than in those with only one infection.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A new study that found the risk of Long COVID doubled in children following SARS-C0V-2 reinfection made mainstream headlines this week
· Researchers in Japan may have found a potential biomarker and treatment target for cognitive dysfunction in #LongCOVID
· A new phase 1 clinical trial is currently recruiting to test the GLP-1 agonist drug Liraglutide for Long COVID, multiple sclerosis, and acute leukemia
Research updates, October 7 - The Sick Times
A new study that found the risk of Long COVID doubled in children following SARS-C0V-2 reinfection made mainstream headlines this week.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A new study that found the risk of Long COVID doubled in children following SARS-C0V-2 reinfection made mainstream headlines this week
· Researchers in Japan may have found a potential biomarker and treatment target for cognitive dysfunction in #LongCOVID
· A new phase 1 clinical trial is currently recruiting to test the GLP-1 agonist drug Liraglutide for Long COVID, multiple sclerosis, and acute leukemia
Research updates, October 7 - The Sick Times
A new study that found the risk of Long COVID doubled in children following SARS-C0V-2 reinfection made mainstream headlines this week.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A large electronic health records study found SARS-CoV-2 infection is associated with elevated risks of Human Papillomavirus (HPV)-related cancer
· A small study in the Journal of Translation Medicine found a potential blood test for myalgic encephalomyelitis (ME)
· Researchers have developed a device that may be able to accurately measure fibrinaloid microclots in children
Research updates, October 14 - The Sick Times
A large electronic health records study found SARS-CoV-2 infection is associated with elevated risks of Human Papillomavirus (HPV)-related cancer.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A large electronic health records study found SARS-CoV-2 infection is associated with elevated risks of Human Papillomavirus (HPV)-related cancer
· A small study in the Journal of Translation Medicine found a potential blood test for myalgic encephalomyelitis (ME)
· Researchers have developed a device that may be able to accurately measure fibrinaloid microclots in children
Research updates, October 14 - The Sick Times
A large electronic health records study found SARS-CoV-2 infection is associated with elevated risks of Human Papillomavirus (HPV)-related cancer.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for #LongCOVID
· A white paper from the Patient-Led Research Collaborative assessed Long COVID in India
· Researchers recently critiqued the study design and conclusions of a controversial 2024 study on ME, which asserted that the disease was a result of altered “effort preference” and deconditioning
Research updates, October 21 - The Sick Times
A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for Long COVID, according to a new study published in JAMA Internal Medicine. The randomized trial included 346 participants in India who took at least 0.5 milligrams once or twice per day, or a placebo, for 52 weeks.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for #LongCOVID
· A white paper from the Patient-Led Research Collaborative assessed Long COVID in India
· Researchers recently critiqued the study design and conclusions of a controversial 2024 study on ME, which asserted that the disease was a result of altered “effort preference” and deconditioning
Research updates, October 21 - The Sick Times
A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for Long COVID, according to a new study published in JAMA Internal Medicine. The randomized trial included 346 participants in India who took at least 0.5 milligrams once or twice per day, or a placebo, for 52 weeks.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A small mechanistic study in Frontiers in Immunology analyzed chronic inflammation in #COVID19.
· A recent paper found that low-dose rapamycin alleviated symptoms of fatigue and post-exertional malaise in people with #MECFS.
· A phase 2 clinical trial is recruiting in Boston, Massachusetts to test the drugs Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) for ME.
Research updates, October 28 - The Sick Times
A small mechanistic study in Frontiers in Immunology analyzed chronic inflammation in COVID-19. Researchers assessed over 70,000 blood cells from eight participants across different disease states.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· A small mechanistic study in Frontiers in Immunology analyzed chronic inflammation in #COVID19.
· A recent paper found that low-dose rapamycin alleviated symptoms of fatigue and post-exertional malaise in people with #MECFS.
· A phase 2 clinical trial is recruiting in Boston, Massachusetts to test the drugs Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) for ME.
Research updates, October 28 - The Sick Times
A small mechanistic study in Frontiers in Immunology analyzed chronic inflammation in COVID-19. Researchers assessed over 70,000 blood cells from eight participants across different disease states.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· The #German government is cutting millions of euros in #LongCOVID funding
· Large electronic cohort study from Sweden found that 1.4% of people with a documented #COVID19 case were officially diagnosed with Long COVID by medical providers
· Lidia Morawska, Australian scientist who alerted the world that SARS-CoV-2 was airborne, was recently recognized for her work with a prestigious science prize for “pioneering research about the air we breathe"
Research updates, November 4 - The Sick Times
The German government is cutting millions of euros in Long COVID funding, according to the German business newspaper Handelsblatt.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· The #German government is cutting millions of euros in #LongCOVID funding
· Large electronic cohort study from Sweden found that 1.4% of people with a documented #COVID19 case were officially diagnosed with Long COVID by medical providers
· Lidia Morawska, Australian scientist who alerted the world that SARS-CoV-2 was airborne, was recently recognized for her work with a prestigious science prize for “pioneering research about the air we breathe"
Research updates, November 4 - The Sick Times
The German government is cutting millions of euros in Long COVID funding, according to the German business newspaper Handelsblatt.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· The RECOVER-NEURO clinical trial found that “cognitive rehabilitation” failed in treating #LongCOVID
· Scientists are revealing more about microclots and Long COVID. A recent study in the Journal of Medical Virology found a strong association between microclots and net-like structures that some white blood cells (called neutrophils) release to attack pathogens
· A study about #MECFS was retracted by the journal Food Science and Nutrition
Research updates, November 11 - The Sick Times
The RECOVER-NEURO clinical trial found that “cognitive rehabilitation” failed in treating Long COVID. The National Institutes of Health (NIH) study included 328 people who underwent interventions of either online cognitive training (computer games), a cognitive rehabilitation program, or received electric currents on their heads.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· The RECOVER-NEURO clinical trial found that “cognitive rehabilitation” failed in treating #LongCOVID
· Scientists are revealing more about microclots and Long COVID. A recent study in the Journal of Medical Virology found a strong association between microclots and net-like structures that some white blood cells (called neutrophils) release to attack pathogens
· A study about #MECFS was retracted by the journal Food Science and Nutrition
Research updates, November 11 - The Sick Times
The RECOVER-NEURO clinical trial found that “cognitive rehabilitation” failed in treating Long COVID. The National Institutes of Health (NIH) study included 328 people who underwent interventions of either online cognitive training (computer games), a cognitive rehabilitation program, or received electric currents on their heads.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· New mechanistic study in Science Translational Medicine identifies Epstein-Barr virus as a potential trigger of the autoimmune disease systemic #lupus erythematosus
· Michael Peluso of UCSF shared updates on two upcoming #LongCOVID trials:
- One potential trial called COMBAT-LC plans to test the combination of the monoclonal antibody Pemgarda with the antiviral Paxlovid
- The second trial INTERRUPT-LC will test the bladder cancer drug Anktiva
Research updates, November 18 - The Sick Times
A new mechanistic study in Science Translational Medicine identifies Epstein-Barr virus (EBV) as a potential trigger of the autoimmune disease systemic lupus erythematosus.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
-
· New mechanistic study in Science Translational Medicine identifies Epstein-Barr virus as a potential trigger of the autoimmune disease systemic #lupus erythematosus
· Michael Peluso of UCSF shared updates on two upcoming #LongCOVID trials:
- One potential trial called COMBAT-LC plans to test the combination of the monoclonal antibody Pemgarda with the antiviral Paxlovid
- The second trial INTERRUPT-LC will test the bladder cancer drug Anktiva
Research updates, November 18 - The Sick Times
A new mechanistic study in Science Translational Medicine identifies Epstein-Barr virus (EBV) as a potential trigger of the autoimmune disease systemic lupus erythematosus.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
· A review paper summarizes the vast global costs of #LongCOVID, it is estimated to have an average annual burden of at least $1 trillion globally per year
· A small study in Nature found SARS-CoV-2 in the organs of fetuses from people who were infected with the virus while pregnant
· The National Institutes of Health’s RECOVER-Treating Long COVID initiative released a draft of its protocol for the low-dose naltrexone trial for people ages 6-25
Research updates, November 25 - The Sick Times
A new review paper summarizes the vast global costs of Long COVID. Public health researcher Amit Bansal from the University of Bergen conducted an economic literature analysis and determined that Long COVID is estimated to have an average annual burden of at least $1 trillion globally each year.
The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)
